New Rules of Biotech Now in Hardcover and Audiobook

David Craig, a seasoned biotechnology founder and industry operator, has released his book The New Rules of Biotech: A Founder’s Guide to Building Great Companies in hardcover and audiobook formats, expanding on the previously available paperback and Kindle editions. The book addresses the fundamental shifts in the biotech landscape since 2021, where capital is scarcer, FDA standards have tightened, and the Inflation Reduction Act has altered drug economics. Craig draws from his experience founding Sarcomatrix Therapeutics Corp. to offer practical guidance on company building—from choosing between platforms and assets to navigating seed rounds, non-dilutive capital, IND-enabling work, and eventual exits like acquisitions or IPOs. The book is designed for founders, investors, board members, and operators, with tailored takeaways for each audience. The new formats cater to readers who prefer physical copies or on-the-go listening, ensuring the message reaches a wider audience.

Craig’s motivation stems from a personal connection to a rare genetic muscle disease, RYR-1 related congenital muscular dystrophy, which underscores the book’s emphasis on responsibility beyond financial returns. The book is published by D. Craig Consulting LLC and is available on Amazon and Google Play. Media contact is Madelyn De Los Santos at Putnam Insights. The release was distributed via NEWMEDIAWIRE and can be viewed on www.newmediawire.com.

This release matters because it provides a timely, actionable playbook for navigating the current biotech environment, where old strategies no longer work. Craig’s insights help founders and investors make smarter decisions, potentially accelerating life-saving therapies to patients while ensuring capital efficiency. The inclusion of personal motivation adds a human element, reminding readers that biotech innovation carries profound societal impact.